Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 26 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1840 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS